![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 75.00 | 73.00 | 77.00 | 75.00 | 75.00 | 75.00 | 8,804 | 08:00:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -6.93 | 49.49M |
RNS Number:7339H Celsis International PLC 31 July 2001 Embargo: 7.00am, Tuesday 31 July 2001 CELSIS INTERNATIONAL PLC AGM STATEMENT The following is an extract from a statement made by Mr Derek Pearce, Deputy Chairman of Celsis, at today's Annual General Meeting. "In the report and accounts for the year ended 31 March 2001 we reported that during the year the Board appointed a new management team to Celsis headed by Mr Jay LeCoque, Celsis' new Chief Executive. Together with Mr Christian Madrolle, as new Finance Director, and Dr Peter Grant as Director of Technology and Business Development, this new team has brought strong, hands-on experience to Celsis; to deliver the potential that Celsis has is in the field of rapid microbial testing. "In the last six months of the year Celsis has been restructured to correct the lack of performance in the European dairy sector. For the first time Celsis has now a unified global approach to sales and marketing. The final part of Celsis' restructure followed the acquisition of ConCell in March 2001. This acquisition not only removes a competitor, from the dairy sector, but also provides Celsis with high performance instrumentation and reagent technology with which to leverage its world-wide position, in the dairy sector, going forward. "The Global Corporate Account Management (GCAM) programme will continue to expand Celsis' leadership position in the pharmaceutical and personal care product sectors. Celsis continues to focus on new site implementations, as well as the number of products tested per site, to generate increased sales from global blue chip companies. "The new management team have completed a review of operations, during the second half of last year, which has resulted in the adoption of a new global sales policy. This change has meant that Celsis has also needed to change the revenue recognition policy for the products business. This new policy recognises a sale when a written commitment, to implement the Celsis technology, has been received from the customer. Previously a sale was recognised on dispatch of an instrument. These changes mean that Celsis has a strong base from which future growth in the business can be accurately predicted. "Celsis Laboratory Group (CLG) delivered exceptional results this year and have excelled under its new management structure. CLG is determined to continue its rapid growth by offering its customers the highest quality standards of analysis with competitive turnaround times. "Following the changes and restructuring made last year, Celsis is looking forward to years of stable growth ahead". Enquiries Celsis International plc Jay LeCoque, Chief Executive Jenny Parsons, Corporate Communications +44-1223-426008 Notes to Editors Celsis International plc Celsis International plc is a world leader in the development and supply of rapid diagnostic and monitoring systems to detect and measure microbial contamination in finished products bound for consumers. It has successfully developed tests for use in the pharmaceutical, cosmetic and toiletries, food and beverage industries. These tests are based upon the years of research in enzyme technology that employ numerous methods for the rapid detection of microbial contamination. Celsis International plc also has a leading laboratory services company servicing the pharmaceutical and cosmetic and toiletries industries, which operates primarily in the United States.
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions